This site is intended for health professionals only

Published on 20 March 2009

Share this story:
Twitter
LinkedIn

Post surgery treatment for GIST

teaser

Novartis has received a positive opinion supporting European Union (EU) approval of Glivec (imatinib) as a post-surgery treatment for patients at significant risk of relapse following removal of gastrointestinal stromal tumors (GIST).

The Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Glivec based on positive findings from a pivotal Phase III study, which showed that use of Glivec after surgery reduces risk of recurrence by approximately 89%. The European Commission generally follows the recommendations of the CHMP and delivers its final decision within two to three months. The decision will apply in all 27 EU member states plus Iceland and Norway.

“This positive opinion is an important step forward for GIST patients,” said David Epstein, President and CEO, Novartis Oncology, Novartis Molecular Diagnostics. “If approved in Europe, Glivec would provide an immediate option for post surgical protection against the return of this highly aggressive disease.”

GIST is a life-threatening cancer of the gastrointestinal tract. After initial removal, it can return in as many as one out of two patients within a median of two years. If approved for this new use, Glivec would be the first and only treatment indicated for use after surgery to delay the return of this highly aggressive cancer.  In the EU, Glivec is currently indicated for the first line treatment of metastatic or unresectable (inoperable) Kit (CD117) positive GIST, the treatment of all phases of Philadelphia chromosome-positive chronic myeloid leukemia (CML), and other rare cancers. This would be the tenth indication approved for Glivec in the EU. Glivec is already approved for this new indication in the US, Switzerland and several other countries.

Novartis



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn